Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors

Shifali Shishodia, Marina Demetriades, Dong Zhang, Nok Yin Tam, Pratheesh Maheswaran, Caitlin Clunie-O'Connor, Anthony Tumber, Ivanhoe K.H. Leung, Yi Min Ng, Thomas M. Leissing, Afaf H. El-Sagheer, Eidarus Salah, Tom Brown, Wei Shen Aik*, Michael A. McDonough*, Christopher J. Schofield*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

FTO catalyzes the Fe(II) and 2-oxoglutarate (2OG)-dependent modification of nucleic acids, including the demethylation of N6-methyladenosine (m6A) in mRNA. FTO is a proposed target for anti-cancer therapy. Using information from crystal structures of FTO in complex with 2OG and substrate mimics, we designed and synthesized two series of FTO inhibitors, which were characterized by turnover and binding assays, and by X-ray crystallography with FTO and the related bacterial enzyme AlkB. A potent inhibitor employing binding interactions spanning the FTO 2OG and substrate binding sites was identified. Selectivity over other clinically targeted 2OG oxygenases was demonstrated, including with respect to the hypoxia-inducible factor prolyl and asparaginyl hydroxylases (PHD2 and FIH) and selected JmjC histone demethylases (KDMs). The results illustrate how structure-based design can enable the identification of potent and selective 2OG oxygenase inhibitors and will be useful for the development of FTO inhibitors for use in vivo.

Original languageEnglish
Pages (from-to)16609-16625
Number of pages17
JournalJournal of Medicinal Chemistry
Volume64
Issue number22
Early online date11 Nov 2021
DOIs
Publication statusPublished - 25 Nov 2021

Scopus Subject Areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors'. Together they form a unique fingerprint.

Cite this